Pathogenesis, Non-Invasive Assessments and Treatment of Hepatic Fibrosis in Autoimmune Liver Diseases.

Background And Aims: Autoimmune liver diseases (AILD), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), can lead to progressive liver fibrosis, development of cirrhosis, decompensation, hepatocellular carcinoma (HCC), and need for liver transplantation (LT).

Methods: This review aims to provide a comprehensive overview of the mechanisms of liver fibrogenesis, non-invasive methods to assess hepatic fibrosis and potential anti-fibrotic interventions in AILD.

Results And Conclusions: Current management for AILD should incorporate non-invasive methods to evaluate changes in hepatic fibrosis and consider potential interventions aiming at controlling the progression of the disease, interruption and, potentially, reversal of liver fibrosis.

PSC-specific prognostic scores associated with graft loss and overall mortality in recurrent PSC after liver transplantation.

Background: Primary sclerosing cholangitis (PSC) is a progressive liver disease with no treatment apart from liver transplantation (LT). After LT, patients can develop recurrent PSC (rPSC). The United-Kingdom (UK-PSC) and Amsterdam-Oxford (AOPSC) scores are used as prognostic models for PSC outcomes.

A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.

Purpose: We report the impact of 1 vs. 2 doses of mitomycin-C (MMC) based chemoradiation (CRT) on patterns of treatment failure and long-term patient outcomes in anal squamous cell carcinoma (ASCC) and the predictors for locoregional failure (LRF) and distant metastasis (DM).

Methods: In this population-based study, we identified all patients with anal cancer in our province treated radically with radiation and concurrent 5-Fluorouracil (5FU) and 1 vs.